GlassScriptPhysician profile
Sara Kabir
NPI 1568902377
$1,272.49
in general payments reported to CMS, 2019-2025
18 companies · $106 in 2025
The $106 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $112 · 2021: $238 · 2022: $87.96 · 2023: $344 · 2024: $385 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $201.61 | 2021-2024 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.57 | 2021-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $130.19 | 2021-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $123.81 | 2021-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $120.65 | 2020-2024 | Xarelto |
| Pfizer INC. | $100.95 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $94.25 | 2020-2024 | |
| Mallinckrodt Hospital Products INC. | $60.70 | 2024 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $36.60 | 2025 | |
| Allergan, INC. | $35.91 | 2020 | |
| Ferring Pharmaceuticals INC. | $32.52 | 2024 | Rebyota |
| Alcresta Therapeutics, INC. | $31.98 | 2024 | Relizorb |
| Genzyme Corporation | $24.70 | 2021 | |
| Mylan Specialty L.P. | $23.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.52 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $21.62 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.99 | 2023 | Lifevest |
| Gilead Sciences, INC. | $16.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Kabir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.